{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:51:22Z","timestamp":1787237482510,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000102","name":"health resources and services administration","doi-asserted-by":"publisher","award":["T25HP37593"],"award-info":[{"award-number":["T25HP37593"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"name":"massachusetts bureau of substance addiction services","award":["RFR #163274"],"award-info":[{"award-number":["RFR #163274"]}]},{"DOI":"10.13039\/100000025","name":"national institute of mental health","doi-asserted-by":"crossref","award":["U01MH121954"],"award-info":[{"award-number":["U01MH121954"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the United States, methadone for opioid use disorder (OUD) is limited to highly regulated opioid treatment programs (OTPs), rendering it inaccessible to many patients. The \u201c72-hour rule\u201d allows non-OTP providers to administer methadone for emergency opioid withdrawal management while arranging ongoing care. Low-barrier substance use disorder (SUD) bridge clinics provide rapid access to buprenorphine but offer an opportunity to treat acute opioid withdrawal while facilitating OTP linkage. We describe the case of a patient with OUD who received methadone for opioid withdrawal in a bridge clinic and linked to an OTP within 72\u00a0h.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 54-year-old woman with severe OUD was seen in a SUD bridge clinic requesting OTP linkage and assessed with a clinical opiate withdrawal scale (COWS)\u00a0score of 12. She reported daily nasal use of 1\u00a0g heroin\/fentanyl. Prior OUD treatment included buprenorphine-naloxone, which was only partially effective. Her acute opioid withdrawal was treated with a single observed oral dose of methadone 20\u00a0mg. She returned the following day with persistent opioid withdrawal (COWS\u00a0score 11) and was treated with methadone 40\u00a0mg. On day 3, the patient was successfully admitted to a local OTP, where she remained engaged 3\u00a0months later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While patients continue to face substantial access barriers, bridge clinics can play an important role in treating opioid withdrawal, building partnerships with OTPs to initiate methadone on demand, and preventing life-threatening delays to methadone treatment. Federal policy reform is urgently needed to make methadone more accessible to people with OUD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-021-00279-x","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T20:02:53Z","timestamp":1640635373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7419-7542","authenticated-orcid":false,"given":"Jordana","family":"Laks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalija M.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Komaromy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kolodziej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Y.","family":"Walley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"279_CR1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306256","author":"J Friedman","year":"2021","unstructured":"Friedman J, Akre S. COVID-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January\u2013July 2020. Am J Public Health. 2021. https:\/\/doi.org\/10.2105\/AJPH.2021.306256.","journal-title":"Am J Public Health"},{"key":"279_CR2","unstructured":"Data Brief: Opioid-related overdose deaths among Massachusetts Residents. 2021. https:\/\/www.mass.gov\/doc\/opioid-related-overdose-deaths-among-ma-residents-may-2021\/download. Accessed 22 Oct 2021."},{"key":"279_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0976","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976.","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"279_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2009.10.004","volume":"21","author":"RD Bruce","year":"2010","unstructured":"Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease hiv incidence rates in resource limited settings. Int J Drug Policy. 2010;21(2):122\u20134. https:\/\/doi.org\/10.1016\/j.drugpo.2009.10.004.","journal-title":"Int J Drug Policy"},{"key":"279_CR5","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.12411","author":"SM Alavian","year":"2013","unstructured":"Alavian SM, Mirahmadizadeh A, Javanbakht M, et al. Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon. 2013. https:\/\/doi.org\/10.5812\/hepatmon.12411.","journal-title":"Hepat Mon"},{"key":"279_CR6","unstructured":"Subpart C. Certification and Treatment Standards for Opioid Treatment Programs. 2021. https:\/\/www.govregs.com\/regulations\/title42_chapterI_part8_subpartC. Accessed 28 April 2021."},{"issue":"8","key":"279_CR7","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","volume":"105","author":"CM Jones","year":"2015","unstructured":"Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55-63. https:\/\/doi.org\/10.2105\/AJPH.2015.302664.","journal-title":"Am J Public Health"},{"key":"279_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/948789","volume":"2011","author":"A Rosenblum","year":"2011","unstructured":"Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011;2011: e948789. https:\/\/doi.org\/10.1155\/2011\/948789.","journal-title":"J Environ Public Health"},{"key":"279_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ypmed.2015.04.017","volume":"80","author":"SC Sigmon","year":"2015","unstructured":"Sigmon SC. Interim treatment: bridging delays to opioid treatment access. Prev Med. 2015;80:32\u20136. https:\/\/doi.org\/10.1016\/j.ypmed.2015.04.017.","journal-title":"Prev Med"},{"issue":"4","key":"279_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jsat.2011.06.005","volume":"41","author":"J Gryczynski","year":"2011","unstructured":"Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH. Patterns in admission delays to outpatient methadone treatment in the United States. J Subst Abuse Treat. 2011;41(4):431\u20139. https:\/\/doi.org\/10.1016\/j.jsat.2011.06.005.","journal-title":"J Subst Abuse Treat"},{"key":"279_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsat.2018.08.009","volume":"94","author":"A Lo","year":"2018","unstructured":"Lo A, Kerr T, Hayashi K, et al. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs. J Subst Abuse Treat. 2018;94:41\u20136. https:\/\/doi.org\/10.1016\/j.jsat.2018.08.009.","journal-title":"J Subst Abuse Treat"},{"key":"279_CR12","unstructured":"PART 1306 - Section 1306.07 Administering or dispensing of narcotic drugs. 2021. https:\/\/www.deadiversion.usdoj.gov\/21cfr\/cfr\/1306\/1306_07.htm. Accessed 29 April 2021."},{"key":"279_CR13","doi-asserted-by":"publisher","DOI":"10.4172\/2324-9005.1000138","author":"A Noska","year":"2015","unstructured":"Noska A, Mohan A, Wakeman S, Rich J, Boutwell A. Managing opioid use disorder during and after acute hospitalization: a case-based review clarifying methadone regulation for acute care settings. J Addict Behav Ther Rehabil. 2015. https:\/\/doi.org\/10.4172\/2324-9005.1000138.","journal-title":"J Addict Behav Ther Rehabil"},{"issue":"4","key":"279_CR14","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1097\/ADM.0000000000000682","volume":"14","author":"M Harris","year":"2020","unstructured":"Harris M, Johnson S, Mackin S, Saitz R, Walley AY, Taylor JL. Low barrier tele-buprenorphine in the time of COVID-19: a case report. J Addict Med. 2020;14(4):e136\u20138. https:\/\/doi.org\/10.1097\/ADM.0000000000000682.","journal-title":"J Addict Med"},{"key":"279_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.09.003","volume":"107","author":"RL Snow","year":"2019","unstructured":"Snow RL, Simon RE, Jack HE, Oller D, Kehoe L, Wakeman SE. Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic. J Subst Abuse Treat. 2019;107:1\u20137. https:\/\/doi.org\/10.1016\/j.jsat.2019.09.003.","journal-title":"J Subst Abuse Treat"},{"key":"279_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000801","author":"L Harvey","year":"2021","unstructured":"Harvey L, Taylor JL, Assoumou SA, et al. Sexually transmitted and blood-borne infections among patients presenting to a low-barrier substance use disorder medication clinic. J Addict Med. 2021. https:\/\/doi.org\/10.1097\/ADM.0000000000000801.","journal-title":"J Addict Med"},{"key":"279_CR17","doi-asserted-by":"publisher","DOI":"10.17226\/25310","volume-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences, Engineering and Medicine","year":"2019","unstructured":"National Academies of Sciences, Engineering and Medicine. Medications for opioid use disorder save lives. Wastington DC: National Academic Press; 2019. https:\/\/doi.org\/10.17226\/25310."},{"key":"279_CR18","unstructured":"The Biden-Harris Administration\u2019s Statement of Drug Policy Priorities for Year One. https:\/\/www.whitehouse.gov\/wp-content\/uploads\/2021\/03\/BidenHarris-Statement-of-Drug-Policy-Priorities-April-1.pdf?fbclid=IwAR2TBk34U_XRqlqK_pAYnUd_9f7zY3IbCQI9KxI6S5eYeRJdFzl9B09hZ84. Accessed 22 Oct 2021."},{"issue":"6","key":"279_CR19","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s11606-018-4801-3","volume":"34","author":"SL Calcaterra","year":"2019","unstructured":"Calcaterra SL, Bach P, Chadi A, et al. Methadone matters: what the united states can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;34(6):1039\u201342. https:\/\/doi.org\/10.1007\/s11606-018-4801-3.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"279_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMp1803982","volume":"379","author":"JH Samet","year":"2018","unstructured":"Samet JH, Botticelli M, Bharel M. Methadone in primary care\u2014one small step for congress, one giant leap for addiction treatment. N Engl J Med. 2018;379(1):7\u20138. https:\/\/doi.org\/10.1056\/NEJMp1803982.","journal-title":"N Engl J Med"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-021-00279-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-021-00279-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-021-00279-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T20:04:23Z","timestamp":1640635463000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-021-00279-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["279"],"URL":"https:\/\/doi.org\/10.1186\/s13722-021-00279-x","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"22 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient described provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}